A polyelectrolyte synthesized from cis-1,4-polyisoprene, containing aminosulfonate and carboxylate groups was shown to have an anticoagulant activity of about 1/30 compared with heparin. Because the substance prevents the coagulation of plasma in the presence of thrombin it is assumed that it acts as an antithrombin.
In seeking new thromboresistant polymeric materials we investigated the activit!y of A as an anticoagulant. The present results indicate that A acts as an antithrombin, with an activity of about 1/30 compared with heparin.
MATERIALS AND METHODS
The polyelectrolyte A was synthesized as described.' Citrated human and bovine plasma were stored a t -26°C before use. Human plasma had a concentration of about 1.8.10-2 M disodium citrate and 2.0.10-2 M glucose. Prior to use the pH of the plasma was adjusted to 7.35 (unless otherwise stated) with the aid of 0.15 M HCl or 0.15 M Na2C03.
Recalcification times of plasma were measured in Pyrex tubes with an outer diameter of 1.0 cm at 37°C. Part of the experiments were followed in an optical way as described by Matthews et al.3 For this purpose a Vitatron colorirneter, Model UC 200 S, was used, equipped with a special thermostated vessel holder for the test tubes. Further, a 2 mm thick heat filter was placed between the lamp and vessel holder. Recalcification was carried out with 0.3 M CaClz (pH 7.35) to a final concentration of 1.9.10-2 M to 3.5.10-2 M of added CaC12. Heparin, 152 E/mg, was purchased from Diosynth (Oss, Holland). Thrombin in 0.05 M phosphate buffer (pH 7.0), 250 NIH units/ml, was obtained from Sigma.
Stock solutions of 12 mg/ml for both heparin and A were used for all measurements. The pH of these solutions was adjusted to 7.35 prior to use.
RESULTS AND DISCUSSION
The anticoagdant activity of A compared with heparin in human plasma, is shown in Table I .
At concentrations up to about 0.4 mg A/ml plasma a real coagulation of the plasma took place after recalcification. In the case of 0.4 mg A/ml plasma the coagulation started after approximately 20 min and was completed in about 40 min. When the concentration was 0.8 mg A/ml, only some precipitate was formed at the interface of plasma and air after about 5 hr. When the experiment was continued longer than 8 hr a precipitate was also observed in the liquid. A similar behavior was found when heparin was present in a concentration of 0.04 mg/ml plasma. When the concentration of A was 1.2 mg/ml no clotting or precipitation occurred even after 8 hr. From the experiments it follows that the activity of A in preventing clot formation is about 1/20 compared with heparin.
In Table I1 data on some coagulation experiments with bovine plasma in the presence of A are listed, for different concentrations of added CaC12 and different pH values. At low Ca2+ concentrations the coagulation times of plasma in the presence of A were less than those at high Ca2f concentrations. The anticoagulant effect of A cannot be explained, however, by assuming a complex between A and Ca2+. For instance, in the case of 0.2 mg A/ml plasma and 3.5.10-2 M CaClz only 2% of the Ca2+ can be complexed, when it is assumed that the whole polymer consists of those units shown in the preceding structure (based on a ratio 1 unit: 1 Ca2+). Furthermore, a conductometric titration of A and Ca2+ did not indicate any complex formation. The anticoagulant activity is also not caused by a "soap-eff ect" of the polyelectrolyte. Comparable amounts of sodium dodecylsulfate even enhanced the clotting of plasma. No significant differences in recalcification times were found for the experiments in which pH values of 7.37 and 7.98 were used.
The coagulation of bovine plasma is prevented at much lower concentrations of both the anticoagulants A and heparin compared to human plasma. Because more precipitate is formed in bovine plasma than in human plasma during freezing, larger amounts of denaturated clotting factors may be present in the precipitate of bovine plasma.
A comparable polymer was synthesized, starting from 3,4-polyisoprene and N-chlorosulfonyl isocyanate. From the IR spectrum of the addition product it was expected that the alkaline hydrolysis product should contain less NH-S03Na-groups. In agreement with this assumption, the anticoagulant activity of this compound was found to be 4 to 5 times lower compared to A. A similar polymer derived from poly(2,3-dimethylbutadiene), which probably contains even fewer NH-S03Na-groups, was found to be even less active.
In Table I11 data from some experiments are given, in which thrombin, together with a small amount of CaC12, was added to bovine plasma that had been incubated with A or heparin. In the presence of 1.67 NIH units thrombin/ml plasma and 1.9.10-2 M Ca2+ the coagulation time of plasma without an anticoagulant was about 30 sec. In the presence of A or heparin the coagulation of the plasma is strongly delayed. The fact that A prevents the clotting of plasma in the presence of thrombin indicates that it acts as an antithrombin. Whether A also interferes in earlier stages of the blood coagulation process is not yet known. From the experiments, listed in Table 111 , in which the course of the clotting was also considered, it followed that the antithrombin activity of A is 1/20 to 1/40 compared with heparin. This order of magnitude is the same as the anticoagulant activity that can be derived from the Tables I and 11 .
Attempts will be made to synthesize an insoluble polymer derived from A. This can be done either by starting from a partly crosslinked cis-1,4-polyisoprene or by crosslinking the final product A.
